Evidence map›Paper›PMID 35699239›Full record

ArticleRenal failure2022

Transcriptional profile changes after treatment of ischemia reperfusion injury-induced kidney fibrosis with 18β-glycyrrhetinic acid.

Yamei Jiang, Chengzhe Cai, Pingbao Zhang, Yongsheng Luo, Jingjing Guo, Jiawei Li, Ruiming Rong, Yi Zhang, Tongyu Zhu

Open access · goldAbstract read
In one paragraph

Article in Renal failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yamei JiangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.ORCID 0000-0002-7709-7328
Chengzhe CaiDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Pingbao ZhangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Yongsheng LuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Jingjing GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Jiawei LiDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Ruiming RongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Yi ZhangShanghai Key Laboratory of Organ Transplantation, Shanghai, P. R. China.
Tongyu ZhuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
Sun Yat-sen University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic kidney disease (CKD) is characterized by renal fibrosis without effective therapy. 18β-Glycyrrhetinic acid (GA) is reported to have detoxification and anti-inflammatory functions and promotes tissue repair. However, the role of GA in CKD remains unclear. In this study, we investigated whether GA has a potential therapeutic effect in kidney fibrosis.

methodsA renal fibrosis mouse model was established by ischemia/reperfusion (I/R) injury via clamping unilateral left renal pedicle for 45 min; then, the mice were treated with vehicle or GA. Kidney tissues and blood samples were extracted 14 days after reperfusion and renal function, histopathological staining, quantitative PCR, and western blotting were performed. RNA-seq was performed to explore the changes in the transcriptional profile after GA treatment.

resultsRenal function, pathological and molecular analysis displayed that fibrosis was successfully induced in the I/R model. In the GA treatment group, the severity of fibrosis gradually reduced with the best effect seen at a concentration of 25 mg kg

conclusionsGA may alleviate renal fibrosis by inhibiting the inflammatory response. GA is a promising therapy that may perhaps be used in treating renal fibrosis and CKD.

Indexed as

Glycyrrhetinic AcidRenal Insufficiency, ChronicReperfusion InjuryAnimalsFibrosisKidneyMice18alpha-glycyrrhetinic acidGlycyrrhetinic Acid18β-Glycyrrhetinic acidfibrosisischemia reperfusion injurykidneyRNA-seqtranscriptional profile

Identifiers

PMID35699239
PMCPMC9225714
OpenAlexW4282927282

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.